Trials / Completed
CompletedNCT02885376
Study of Dentoxol® Mouthrinse for Oral Mucositis
Phase II Study of Dentoxol® Mouthrinse for Oral Mucositis Secondary to Radiation Therapy for Head and Neck Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 108 (actual)
- Sponsor
- Ingalfarma SpA · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine the efficacy of Dentoxol® mouthrinse in reducing the severity of oral mucositis secondary to radiation therapy for head and neck cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Dentoxol | Mouthrinse |
| DEVICE | Placebo | Mouthrinse |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2018-04-01
- Completion
- 2018-08-01
- First posted
- 2016-08-31
- Last updated
- 2018-12-21
Locations
3 sites across 1 country: Chile
Source: ClinicalTrials.gov record NCT02885376. Inclusion in this directory is not an endorsement.